


Delivers a unique BPO formulation to the pores

- Proprietary formulation in CLENZiderm M.D.™ helps bioavailable BPO enter the follicle, where P. acnes is focused^{1,2,5,*†}

CLENZiderm M.D.™ BPO molecule penetrates the hair follicle



CLENZiderm M.D.™ clears acne at the source

- Complete system quickly reduces acne in as early as 1 week^{3,‡} and helps prevent future breakouts^{1,*}
- 5% BPO treats acne-causing P. acnes bacteria within the follicles^{1,2,6,7,*†}
- The majority of patients were satisfied with the improvement in their acne and the system efficacy^{3,‡}

*Study results for a split-face evaluation of the intrafollicular bactericidal activity of a novel BPO formulation. N=24. Obagi Cosmeceuticals LLC. Data on file.
† Study results for a 10-week evaluation of twice-daily use of a 3-step acne system containing a novel solubilized 5% BPO formulation. N=139. Obagi Cosmeceuticals LLC. Data on file.
‡ Study results for a 12-week evaluation of the efficacy and tolerability of daily application of the CLENZiderm M.D.™ System; N=22.



To purchase the CLENZiderm M.D.™ System, talk to your physician today. Find them via www.obagiuk.com

References: 1. Erianne J, Prince DL, Ramirez J, Wilson D, Zeichner J. The pharmacologic science of a novel benzoyl peroxide formulation and the implications for clinical effects. Poster presented at: Clinical Dermatology Conference; October 6-9, 2006; Las Vegas, NV. 2. Thiboutot D, Eichenfield LF, Shalita A, et al. Comparison of a 3-step acne system containing solubilized benzoyl peroxide...Obagi Cosmeceuticals LLC. Data on file. 3. Swinyer L, Investigator. A single-center, open-label study to evaluate the tolerability and efficacy of the optimized CLENZiderm M.D. System for the treatment of mild to moderate facial acne vulgaris. Protocol CLZ-003. 12-week final analysis, January 2012. Obagi Cosmeceuticals LLC. Data on file. 4. Ramirez J, Faryniarz J. Benzoyl peroxide: notes on molecular dimensions. Technical report and microscopic observation. JR Chemical, Inc., Milford, CT; April 18, 2005. Obagi Cosmeceuticals LLC. Data on file. 5. Spellman MC, Ramirez J. A comparison of patterns of deposition of two formulations of benzoyl peroxide on the skin and in the follicular ostia as visualized by scanning electronic microscopy [poster]. Obagi Cosmeceuticals LLC. Data on file. 6. Cotterill JA. Benzoyl peroxide. Acta Derm Venereol Suppl (Stockh). 1980;suppl 89:57-63. 7. Russell JJ. Topical therapy for acne. Am Fam Physician. 2000;61(2):357-365. 8. NIH. Salicylic acid topical. MedlinePlus website. <http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607072.html>. Accessed January 15, 2015.

®/TM are trademarks of Obagi Cosmeceuticals LLC. All other product/brand names are trademarks of the respective owners.
Distributed by Obagi Cosmeceuticals LLC.
©2023 Obagi Medical Products, Inc. All rights reserved.
82183 02/23

CLENZIDERM M.D.™ SYSTEM



Clear your acne from the inside out



Obagi skin is healthy skin

*Study results for a split-face evaluation of the intrafollicular bactericidal activity of a novel BPO formulation...N=24. Obagi Cosmeceuticals LLC. Data on file.
† Study results for a 10-week evaluation of twice-daily use of a 3-step acne system containing a novel solubilized 5% BPO formulation. N=139. Obagi Cosmeceuticals LLC. Data on file.

CLENZIderm M.D.™ gets to the source to treat mild to moderate acne

- Penetrates to reach bacteria in the pores^{1,2,*}
- Reduces breakouts in as little as 1 week with continued results through 12 weeks^{3,†}
- Helps prevent future breakouts^{1,*}

A highly effective, yet tolerable system^{3,‡}

Daily Care Foaming Cleanser	Pore Therapy
 <ul style="list-style-type: none"> • 2% salicylic acid cleanser with calming menthol leaves skin feeling clean and fresh 	 <ul style="list-style-type: none"> • 2% salicylic acid solution unclogs pores and clears away dead skin cells
Therapeutic Lotion	
 <ul style="list-style-type: none"> • Lightweight 5% benzoyl peroxide (BPO) lotion delivers medication within the follicles where acne starts 	

*Study results for a split-face evaluation of the intrafollicular bactericidal activity of a novel BPO formulation...N=24. Obagi Cosmeceuticals LLC. Data on file.

† Study results for a 10-week evaluation of twice-daily use of a 3-step acne system containing a novel solubilised 5% BPO formulation. N=139. Obagi Cosmeceuticals LLC. Data on file.

‡ Study results for a 12-week evaluation of the efficacy and tolerability of daily application of the CLENZIderm M.D.™ System; N=22.

See results as early as week 1^{3,‡}



Baseline[§]

Week 1[§]

[§]Photos have not been retouched. Results may vary.

At week 12^{3,‡}:

- **81%** of patients were satisfied or very satisfied with their acne improvement
- **87%** reported that the system was effective or very effective




Baseline[§]

Week 12[§]

[§]Photos have not been retouched. Results may vary.

‡ Study results for a 12-week evaluation of the efficacy and tolerability of daily application of the CLENZIderm M.D.™ System; N=22.

Early and continuous acne breakout reduction^{3,*}



- Reduces acne breakouts in as little as 1 week^{3,‡}
- Continues to reduce acne lesions through 12 weeks of use^{3,‡}
- Proven effective in treating mild to moderate acne^{3,‡}

Two key ingredients make CLENZIderm M.D.™ effective

5% BPO gets delivered to the follicles to reach the source of acne, P. acnes



Salicylic acid promotes cell turnover to open clogged pores and helps minimise swelling and redness^{7,8}

* Do not use if you have very sensitive skin or are sensitive to benzoyl peroxide. For external use only.

† Study results for a 10-week evaluation of twice-daily use of a 3-step acne system containing a novel solubilised 5% BPO formulation. N=139. Obagi Cosmeceuticals LLC. Data on file.

‡ Study results for a 12-week evaluation of the efficacy and tolerability of daily application of the CLENZIderm M.D.™ System; N=22.